Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer

Sugarman, R., Patel, R., Sharma, S., Plenker, D., Tuveson, D., Saif, M. W. (July 2019) Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer. Expert Opin Drug Metab Toxicol, 15 (7). pp. 541-552. ISSN 1742-5255

URL: https://www.ncbi.nlm.nih.gov/pubmed/31241371
DOI: 10.1080/17425255.2019.1637417

Abstract

INTRODUCTION: Pancreatic cancer (PC) remains a disease with a dismal prognosis. Despite accounting for only 3% of cancer diagnosis, 7% of all cancer deaths in the United States are from PC. This is explained by many being diagnosed with late stage disease and the cancer's resistance to chemotherapy. Since 1996 there have only been two upfront regimens found to be superior to gemcitabine, FOLFIRINOX (5-fluorouracil/leucovorin and oxaliplatin) and gemcitabine plus nab-paclitaxel. Areas covered: We discuss the clinical pharmacology of newer agents that are either approved or being actively investigated in the management of PC. Knowledge of their pharmacokinetics, pharmacodynamics and pharmacogenetics can be used to predict outcomes for specific patient populations. Drugs discussed include nanoliposomal irinotecan, pegvorhyaluronidase alfa, poly (ADP-ribose) polymerase enzyme inhibitors, larotrectinib, and napabucasin. Expert opinion: PC is a heterogeneous disease and outcomes are likely to improve as better predictive models of an individual's response to different therapies are developed. This may be best accomplished through phase 0 studies and the use of tumor organoid models grown from initial biopsies or resected tissue. The genetic and physical makeup of the tumor as well as the functional characterization in patient-derived organoids (PDOs), along with knowledge of a patient's germline mutations, can help guide which agents may be most efficacious or toxic.

Item Type: Paper
Subjects: diseases & disorders > cancer > drugs and therapies > chemotherapy
organs, tissues, organelles, cell types and functions > organs types and functions > metabolism
diseases & disorders > cancer > cancer types > pancreatic cancer
CSHL Authors:
Communities: CSHL labs > Tuveson lab
Depositing User: Matthew Dunn
Date: 3 July 2019
Date Deposited: 08 Aug 2019 14:34
Last Modified: 08 Aug 2019 14:34
Related URLs:
URI: http://repository.cshl.edu/id/eprint/38130

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving